Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. According to data from Dupixent clinical trials, IL-4 and IL-13 are key drivers of type 2 inflammation, which is a major contributor to Atopic...Find More
Cold can make anyone cheerless and miserable, however, having Sinusitis is another story. Also known as rhinosinusitis, Sinusitis makes a person suffer from a stuffy nose, blocked nasal passages, congestion, throbbing pain in eyes, forehead, and cheeks, exhaustion and excess mucous leading to full-blown cold for we...Find More
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studyi...Find More
Sage Therapeutics seeking out to save flunked depression drug Sage Therapeutics has strategized on how to come back from the phase 3 failure of SAGE-217 in major depressive disorder. The plan focuses on three short-term studies Sage contemplates that may enable it to bring the GABA receptor positive allost...Find More
Activated immune cells responsible for improving age-related diseases The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL-5. There has been researching going on, and the researchers at Albany Medical College discovered that if these two signalling molecules ...Find More
Allergic diseases, such as allergic rhinitis (hay fever), food allergy, and eczema, are common allergies that affect people from all over the world. As per CDC, allergies are one of the top ten causes of chronic illness in the USA, afflicting around 50 Million Americans every year. The economic burden of Allergies ...Find More
Sanifit raises USD 80.9 M to advance Calciphylaxis Pipeline Sanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( €72.2 million ) in total private fundraising. The financing mainly consisted led by Spain’s Caixa Capital Risc, along with many new investors, including Columbus Venture ...Find More
Anylam, Regeneron to broaden the scope of R&D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody approach is going to get infused with USD 800 million upfront. The joint deal will help in expanding R&am...Find More
Sanofi and Regeneron Pharmaceuticals got effective results in reducing the risk of major adverse heart events in a clinical study of nearly 19,000 patients with the help of cholesterol drug Praluent. Drugmakers now hope that the results are good enough to convince insurers to pay for the pricey medicine. Treatment w...Find More
Prosecutors rope Pfizer into fast-growing copay assistance probe After first focusing on biotech and speciality pharma, the feds have made their way to Big Pharma, with the New York drug giant joining a group that includes Gilead Sciences, Biogen, Valeant Pharmaceuticals and others about ties to copay assistance pro...Find More
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.